Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | June 18, 2025 | June 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 33,769 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 35,244 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 33,769 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F3: This award is fully vested in accordance with its terms.
MIMEDX GROUP, INC.
Report date June 18, 2025 · Filed June 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,923 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 28,609 · Balance 181,923 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000088 · form4.xml · derivative · entry 5 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,475 | $36.95 | $54,501.25 |
DisclosureSEC source: 0001520262-26-000088 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,769 Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000088 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:00 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000088 · form4.xml · derivative · entry 4 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:00 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000088 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:36 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 28,609 | $6.47 | $185,100.23 |
DisclosureSEC source: 0001376339-25-000066 · wk-form4_1750718197.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,923 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:30 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016200 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:30 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,924 | $30.61 | $58,893.64 |
DisclosureSEC source: 0001127602-25-016200 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,102 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:30 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016200 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:57 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015540 · form4.xml · derivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:57 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015540 · form4.xml · derivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 2,691 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · derivative · entry 6 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,142 Underlying: Ordinary Shares · 2,691 shares Expires 2031-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,691 | $31.85 | $85,708.35 |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 4 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,013 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,691 | $22.52 | $60,601.32 |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| December 08, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · derivative · entry 5 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: This award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| December 08, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 958 | $31.46 | $30,138.68 |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,013 Read SEC document |
| December 08, 2024 Filed Dec 10, 2024 01:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019597 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,465 | $24.10 | $35,306.50 |
DisclosureSEC source: 0001127602-24-019597 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,808 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019597 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 20:30 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 23,190 | $7.26 | $168,359.40 |
DisclosureSEC source: 0001376339-24-000052 · wk-form4_1717705812.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,314 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:54 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017726 · form4.xml · derivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:54 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017726 · form4.xml · derivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 2,690 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,833 Underlying: Ordinary Shares · 2,690 shares Expires 2031-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. F2 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,690 | $31.85 | $85,676.50 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,690 | $22.52 | $60,578.80 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 9 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,163 Underlying: Ordinary Shares · 4,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,000 | $25.86 | $25,860.00 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,169 Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 8 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,326 Underlying: Ordinary Shares · 163 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 7 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,801.86 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 6 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,129.35 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 5 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 422 | $22.52 Strike: $22.52 | $9,503.44 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 4 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,523 Underlying: Ordinary Shares · 422 shares Expires 2031-12-08 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 112 | $22.52 Strike: $22.52 | $2,522.24 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,712 Underlying: Ordinary Shares · 112 shares Expires 2031-12-08 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020548 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,430 | $29.88 | $42,728.40 |
DisclosureSEC source: 0001127602-23-020548 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,006 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020548 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019629 · form4.xml · derivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019629 · form4.xml · derivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:10 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 35,354 | $4.95 | $175,002.30 |
DisclosureSEC source: 0001376339-23-000036 · wk-form4_1686867005.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,124 F1 · shares: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 2,638 | $0.00 Strike: $22.97 | $0.00 |
DisclosureSEC source: 0001127602-23-018291 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,101 Underlying: Ordinary Shares · 2,638 shares Expires 2031-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. F2 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,638 | $31.85 | $84,020.30 |
DisclosureSEC source: 0001127602-23-018291 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,479 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,638 | $22.97 | $60,594.86 |
DisclosureSEC source: 0001127602-23-018291 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $22.97 | $0.00 |
DisclosureSEC source: 0001127602-23-018168 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,600 Underlying: Ordinary Shares · 2,800 shares Expires 2031-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,800 | $31.50 | $88,200.00 |
DisclosureSEC source: 0001127602-23-018168 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,479 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,800 | $22.97 | $64,316.00 |
DisclosureSEC source: 0001127602-23-018168 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,082 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027226 · form4.xml · derivative · entry 6 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,163 Underlying: Ordinary Shares · 4,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027226 · form4.xml · derivative · entry 5 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 378 | $25.48 | $9,631.44 |
DisclosureSEC source: 0001127602-22-027226 · form4.xml · nonDerivative · entry 4 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,479 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.